DALLAS (CBSDFW.COM) – North Texas researchers are on the brink of revolutionizing the way we fight the flu.

Every year, scientists try to guess which strain of the flu will cause the most people to get sick. They use that particular flu bug to make a flu vaccine. But what if you could get one shot that would tackle every single type of flu?

Dena Rushing from Little Elm has not had the flu in years. “Overall, we’re a very healthy family, and very active,” she said. But it is not because she gets the flu shot. She used to get it, but said that she would always get sick. “I can’t remember a year I didn’t, and then I stopped taking it and I stopped getting the flu.”

Continue reading →

Tailored anti-platelet therapy, made possible through a novel point-of-care genetic test, optimizes treatment for patients who carry a common genetic variant, researchers at the University of Ottawa Heart Institute (UOHI) have found.

09 Nov 2011

A UOHI clinical trial known as RAPID GENE studied 200 patients undergoing coronary stent implantation for acute coronary syndrome or stable angina. Use of a simple, saliva swab test performed by nurses at the bedside on half of the patients allowed doctors to almost instantly identify those with the genetic variant, known as CYP2C19*2, which puts them at risk of reacting poorly to standard anti-platelet drug therapy, and administer an alternative drug.

The study demonstrated that tailored drug treatment therapy made possible by the genetic testing successfully protected all of the patients with the at-risk genetic variant from subsequent adverse events, while 30 per cent of patients treated with standard therapy did not receive adequate protection.

Continue reading →